Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6115-67-9

Post Buying Request

6115-67-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6115-67-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 6115-67-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,1,1 and 5 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 6115-67:
(6*6)+(5*1)+(4*1)+(3*5)+(2*6)+(1*7)=79
79 % 10 = 9
So 6115-67-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H13ClN2/c14-8-5-6-12-10(7-8)13(15)9-3-1-2-4-11(9)16-12/h5-7H,1-4H2,(H2,15,16)

6115-67-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 7-chloro-1,2,3,4-tetrahydroacridin-9-amine

1.2 Other means of identification

Product number -
Other names ACRIDINE,1,2,3,4-TETRAHYDRO-9-AMINO-7-CHLORO

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6115-67-9 SDS

6115-67-9Downstream Products

6115-67-9Relevant articles and documents

Design, synthesis and evaluation of cholinesterase hybrid inhibitors using a natural steroidal alkaloid as precursor

Borioni, José L.,Cavallaro, Valeria,Murray, Ana P.,Pe?é?ory, Alicia B.,Puiatti, Marcelo,García, Manuela E.

, (2021/04/22)

To date, Alzheimer's disease is the most alarming neurodegenerative disorder worldwide. This illness is multifactorial in nature and cholinesterase inhibitors have been the ones used in clinical treatments. In this context, many of these drugs selectively inhibit the acetylcholinesterase enzyme interacting in both the active site and the peripheric anionic site. Besides, some agents have exhibited extensive benefits being able to co-inhibit butyrylcholinesterase. In this contribution, a strategy previously explored by numerous authors is reported; the synthesis of hybrid cholinesterase inhibitors. This strategy uses a molecule of recognized high inhibitory activity (tacrine) together with a steroidal alkaloid of natural origin using different connectors. The biological assays demonstrated the improvement in the inhibitory activity compared to the alkaloidal precursor, together with the reinforcement of the interactions in multiple sites of the enzymatic cavity. This strategy should be explored and exploited in this area. Docking and molecular dynamic studies were performed to explain enzyme-ligand interactions, assisting a structure–activity relationship analysis.

Investigation of the reaction of o-aminonitriles with ketones: A new modification of Friedl?nder reaction and structures of its products

Li, Jiarong,Zhang, Lijun,Shi, Daxin,Li, Qing,Wang, Dong,Wang, Chunxia,Zhang, Qi,Zhang, Ling,Fan, Yanqiu

, p. 233 - 236 (2008/12/21)

A new modification of the Friedl?nder reaction is described and the new byproduct obtained from the reaction of o-aminonitriles and ketones was found to be 2,3-dihydroquinazolin-4(1H)-one. The mechanism probably involved the formation of an intermediate o

SAR of 9-amino-1,2,3-4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues

Recanatini, Maurizio,Cavalli, Andrea,Belluti, Federica,Piazzi, Lorna,Rampa, Angela,Bisi, Alessandra,Gobbi, Silvia,Valenti, Piero,Andrisano, Vincenza,Bartolini, Manuela,Cavrini, Vanni

, p. 2007 - 2018 (2007/10/03)

In this study, we attempted to derive a comprehensive SAR picture for the class of acetylcholinesterase (ACHE) inhibitors related to tacrine, a drug currently in use for the treatment of the Alzheimer's disease. To this aim, we synthesized and tested a series of 9-amino-1,2,3,4-tetrahydroacridine derivatives substituted in the positions 6 and 7 of the acridine nucleus and bearing selected groups on the 9-amino function. By means of the Hansch approach, QSAR equations were obtained, quantitatively accounting for both the detrimental steric effect of substituents in position 7 and the favorable electron-attracting effect exerted by substituents in positions 6 and 7 of the 9-amino-1,2,3,4-tetrahydroacridine derivatives. The three-dimensional (3D) properties of the inhibitors were taken into consideration by performing a CoMFA analysis on the series of AChE inhibitors made by 12 9-amino-1,2,3,4- tetrahydroacridines and 13 11H-indeno[1,2-b]quinolin-10-ylamines previously developed in our laboratory. The alignment of the molecules to be submitted to the CoMFA procedure was carried out by taking advantage of docking models calculated for the interactions of both the unsubstituted 9-amino-1,2,3,4- tetrahydroacridine and 11H-indeno[1,2-b]quinolin-10-ylamine with the target enzyme. A highly significant CoMFA model was obtained using the steric field alone, and the features of such a 3D QSAR model were compared with the classical QSAR equations previously calculated. The two models appeared consistent, the main aspects they had in common being (a) the individuation of the strongly negative contribution of the substituents in position 7 of tacrine and (b) a tentative assignment of the hydrophobic character to the favorable effect exerted by the substituents in position 6. Finally, a new previously unreported tacrine derivative designed on the basis of both the classical and the 3D QSAR equations was synthesized and kinetically evaluated, to test the predictive ability of the QSAR models. The 6-bromo-9- amino-1,2,3,4-tetrahydroacridine was predicted to have a pIC50 value of 7.31 by the classical QSAR model and 7.40 by the CoMFA model, while its experimental IC50 value was equal to 0.066 (±0.009) μM, corresponding to a pIC50 of 7.18, showing a reasonable agreement between predicted and observed AChE inhibition data.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6115-67-9